Leica, Synthon Biopharmaceuticals Partner on CDx Development | GenomeWeb

NEW YORK (GenomeWeb News) – Leica Biosystems and Synthon Biopharmaceuticals announced today a collaboration to develop and commercialize companion diagnostics for drugs aimed at treating solid tumors.

The firms will develop companion diagnostics based on Leica's Bond automated advanced staining systems for use with Synthon Bio's antibody-drug conjugates for treating solid tumors. The companies said the deal provides a framework for further collaborations but provided no details about the terms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.